Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic kidney disease with moderate to severe protein in your urine and a certain level of kidney function as measured by blood and urine tests.
- You have high blood pressure (systolic at least 130 mmHg at screening and at least 120 mmHg at randomisation).
- You have been on a stable dose of an ACE inhibitor or ARB (but not both) for at least 4 weeks before screening.
- Your potassium level is within a safe range, which depends on your kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding dapagliflozin to baxdrostat (a new blood pressure drug) reduces protein in urine better than baxdrostat alone in people with chronic kidney disease and high blood pressure. It aims to find a more effective way to protect kidney health.
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
This trial is testing if a new medication called baxdrostat can help lower blood pressure in people who are already taking two or more blood pressure medications but still have uncontrolled high blood pressure. It is for Chinese adults only and will compare the study drug to a placebo (inactive pill).
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Hear when a new Chronic Kidney Disease and Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.